Results 251 to 260 of about 326,057 (302)

Epigenetic priming promotes tyrosine kinase inhibitor resistance and oncogene amplification. [PDF]

Nat Struct Mol Biol
Starble RM, Sun EG, Gbyli R, Radda J, Lu J, Jensen TB, Sun N, Khudaverdyan N, Zhao T, Hu B, Melnick MA, Zhao S, Roper N, Wang GG, Tackett AJ, Wang Y, Song J, Politi K, Wang S, Xiao AZ.   +19 more
europepmc   +1 more source

The ErbB-tyrosine kinase inhibitor, neratinib, has anti-inflammatory effects in multimorbidity by increasing macrophage efferocytosis via the upregulation of MerTK. [PDF]

J Inflamm (Lond)
Bowden KA, Wright C, Clark S, Correa TF, Johnston SA, Marriott HM, Francis SE, Prince LR.   +7 more
europepmc   +1 more source

Successful Management of Tyrosine Kinase Inhibitor-Induced Bone Marrow Aplasia in Chronic Phase Chronic Myeloid Leukemia with Ponatinib: A Case Report and Literature Review. [PDF]

Clin Med Insights Case Rep
Ghasoub R, Shafei L, Taha RY, Soliman D, Elsabah H, Benkharda M, Albattah A, Elomri H.   +7 more
europepmc   +1 more source

Jiedu Xiaozhen Granules for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Mediated Skin Toxicity: Protocol for a Randomized Controlled Trial. [PDF]

JMIR Res Protoc
Hao S, Li X, Hao S, Zhang X, Qi X, Jin G, Shen F, Liu L.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tyrosine Kinase Inhibitors

Current Cancer Drug Targets, 2010
Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinases signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment of several neoplasms, including lung, breast ...
NATOLI, Clara, Perrucci Bruno, Perrotti Francesca, Falchi Lorenzo, IACOBELLI, Stefano, Consorzio Interuniversitario Nazionale per Bio Oncologia   +5 more
openaire   +4 more sources

Inhibitors of tyrosine kinase

Current Opinion in Oncology, 1997
This review covers the literature on significant studies of small molecule inhibitors of the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), Flk-1, and src family tyrosine kinases from 1996 through mid-1997. During this period, there has been substantial progress in the
W D, Klohs, D W, Fry, A J, Kraker
openaire   +2 more sources

Inhibitors of protein tyrosine kinases

Current Opinion in Biotechnology, 1995
The description in the past year of several novel protein tyrosine kinase inhibitors, which exhibit dramatic improvements in potency and specificity over earlier agents, will be considered a major turning point in the field. These compounds appear to have the necessary pharmacological properties to finally allow clarification of whether suppression of ...
D W, Fry, A J, Bridges
openaire   +2 more sources

FLT3 Tyrosine Kinase Inhibitors

International Journal of Hematology, 2005
The receptor tyrosine kinase FLT3 is an important regulatory molecule in hematopoiesis and is expressed on the blasts in most cases of acute leukemia. Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are associated with a distinctly worse clinical outcome.
Mark, Levis, Donald, Small
openaire   +2 more sources